Table 1

General characteristics of the study population

CharacteristicAll participants (N=50)Primary care participants (N=25)BO registry participants (N=17)Previous study participants (N=8)
Age (years), mean (range)63.7 (50–75)60.8 (50–75)67.0 (56–75)66.0 (60–75)
Male gender, n (%)29 (58.0)15 (60.0)10 (58.8)4 (50.0)
White ethnicity, n (%)48 (96.0)24 (96.0)16 (94.1)8 (100.0)
Highest level of education, n (%)
 Primary/high school11 (22.0)5 (20.0)2 (11.8)4 (50.0)
 Vocational college11 (22.0)7 (28.0)4 (23.5)0 (0.0)
 College or university28 (56.0)13 (52.0)11 (64.7)4 (50.0)
Current employment, n (%) yes
 Working full-time14 (28.0)12 (48.0)1 (5.9)1 (12.5)
 Working part-time10 (20.0)3 (12.0)4 (23.5)3 (37.5)
 Unemployed, looking for work1 (2.0)1 (4.0)0 (0.0)0 (0.0)
 Retired25 (50.0)9 (36.0)12 (70.6)4 (50.0)
Current GORD symptoms,* n (%) yes21 (42.0)11 (44.0)7 (41.2)3 (37.5)
Upper endoscopy experience, n (%) yes45 (90.0)21 (84.0)17 (100.0)7 (87.5)
PPI usage, n (%) yes42 (84.0)21 (84.0)16 (94.1)5 (62.5)
BO diagnosis, n (%) yes17 (34.0)0 (0.0)17 (100.0)0 (0.0)
Knowing someone with oesophageal cancer, n (%) yes18 (36.0)9 (36.0)5 (29.4)4 (50.0)
Participant ELECTRONIC study (screening trial), n (%) yes8 (16.0)1 (4.0)4 (23.5)3 (37.5)
Participated in population-based cancer screening programmes, n (%) yes39 (78.0)18 (72.0)14 (82.4)7 (87.5)
  • *Based on a GerdQ32 Score of 8 or higher.

  • GORD, gastro-oesophageal reflux; PPI, proton pump inhibitor; BO, Barrett’s oesophagus.